Related Experiment Video
Updated: Jun 15, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
IgM deposition is a risk factor for delayed remission and early relapse of the pediatric minimal change disease
Tao Ju1, Yingchao Peng2, Yaqin Wei3
1Department of Pediatrics, Jinling Hospital, Nanjing Medical University, Nanjing, China.
Background:
Minimal change disease (MCD) is the most common pathological subtype of pediatric idiopathic nephrotic syndrome (INS). It has been suggested that IgM deposition might predict kidney function deterioration in the course of MCD. However, the specific role of IgM deposition in the prognosis of MCD is still controversial. This study aims to investigate the clinical significance of IgM deposition on delayed remission and early relapse in a pediatric population.
Methods:
This study enrolled 283 children diagnosed with MCD by renal biopsy in a single center from 2010 to 2022. These cases were divided into two groups according to the histopathological deposition of IgM. Patients' demographics, clinical parameters, and follow-up data were collected and analyzed. The primary and secondary outcomes were defined as the time to the first remission and the first relapse.
Results:
The IgM-positive group had a weaker response to steroids (steroid-sensitive: 23.5% vs. 40.8%; steroid-dependent: 74.0% vs. 51.0%; steroid-resistant: 18.4% vs. 8.2%, P = 0.001), and showed more recurrent cases (47.2% vs. 34.4%, P = 0.047) compared with the IgM-negative group. The Kaplan-Meier analysis showed that the IgM-positive group had a lower cumulative rate of the first remission (Log-rank, P < 0.001) and a higher rate of the first relapse (Log-rank, P = 0.034) than the IgM-negative group. Multivariate Cox analysis showed that IgM deposition was independently associated with the delayed first remission (hazard ratio [HR] = 0.604, 95% confidence interval [CI] = 0.465-0.785, P < 0.001) and the early first relapse (HR = 1.593, 95% CI = 1.033-2.456, P = 0.035).
Conclusion:
IgM deposition was associated with a weaker steroid response. MCD children with IgM deposition were prone to delayed first remission and early first relapse.
Insights
Minimal change disease (MCD) in children with IgM deposition shows a poorer response to steroids, leading to delayed remission and earlier relapse. This finding highlights IgM deposition as a significant prognostic factor in pediatric nephrotic syndrome.
Area of Science:
- Nephrology
- Pediatric Nephrology
- Immunopathology
Background:
- Minimal change disease (MCD) is the leading cause of nephrotic syndrome in children.
- The prognostic significance of immunoglobulin M (IgM) deposition in MCD remains debated.
- Investigating IgM's role is crucial for understanding disease progression and treatment strategies.
Purpose of the Study:
- To determine the clinical significance of IgM deposition in pediatric MCD.
- To assess the association between IgM deposition and delayed remission.
- To evaluate the impact of IgM deposition on early relapse rates.
Main Methods:
- Retrospective analysis of 283 pediatric MCD cases diagnosed via renal biopsy.
- Classification into IgM-positive and IgM-negative groups based on histopathology.
- Collection and analysis of demographic, clinical, and follow-up data, including time to remission and relapse.
Main Results:
- IgM-positive patients exhibited significantly weaker responses to steroids (P=0.001) and higher recurrence rates (P=0.047).
- Kaplan-Meier analysis revealed lower cumulative remission rates (P<0.001) and higher relapse rates (P=0.034) in the IgM-positive group.
- Multivariate Cox analysis confirmed IgM deposition as an independent predictor of delayed remission (HR=0.604) and early relapse (HR=1.593).
Conclusions:
- IgM deposition in pediatric MCD is linked to diminished steroid responsiveness.
- Children with IgM deposits in their kidneys are more susceptible to delayed remission and earlier disease relapses.
- IgM deposition serves as a significant indicator for predicting the clinical course of minimal change disease in pediatric patients.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Crohn's Disease